AR098827A1 - ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS - Google Patents
ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOSInfo
- Publication number
- AR098827A1 AR098827A1 ARP140104755A ARP140104755A AR098827A1 AR 098827 A1 AR098827 A1 AR 098827A1 AR P140104755 A ARP140104755 A AR P140104755A AR P140104755 A ARP140104755 A AR P140104755A AR 098827 A1 AR098827 A1 AR 098827A1
- Authority
- AR
- Argentina
- Prior art keywords
- isoform
- tgf
- receptor
- polycucleotid
- peptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Una isoforma del receptor II de TGF b que comprende una secuencia de alrededor de 80 aminoácidos y carece del dominio transmembrana; en donde la isoforma es agonista de TGFb-1. La isoforma comprende a la secuencia de aminoácidos SEQ ID Nº 12. La isoforma puede tener la secuencia de aminoácidos SEQ ID Nº 2 o secuencias que tienen al menos un 85% de identidad de secuencia con la secuencia SEQ ID Nº 2. Reivindicación 5: El polinucleótido de acuerdo con la reivindicación 4, caracterizado porque comprende una secuencia de nucleótidos que tiene al menos un 90% de identidad con la secuencia de nucleótidos SEQ ID Nº 1. Reivindicación 20: Un método de tratamiento de enfermedades asociadas a la desregulación de TGF-b, caracterizado porque comprende administrar a un mamífero que lo necesite el anticuerpo de la reivindicación 17.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361917974P | 2013-12-19 | 2013-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098827A1 true AR098827A1 (es) | 2016-06-15 |
Family
ID=53403721
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104755A AR098827A1 (es) | 2013-12-19 | 2014-12-18 | ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS |
| ARP200101538A AR119056A2 (es) | 2013-12-19 | 2020-05-29 | Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101538A AR119056A2 (es) | 2013-12-19 | 2020-05-29 | Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10233227B2 (es) |
| EP (1) | EP3082846B1 (es) |
| AR (2) | AR098827A1 (es) |
| ES (1) | ES2749615T3 (es) |
| WO (1) | WO2015095628A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR107780A1 (es) * | 2016-11-14 | 2018-06-06 | Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet | Método para determinar la actividad de enfermedades autoinmunes y kit |
| SG11202007927WA (en) | 2018-03-09 | 2020-09-29 | Agenus Inc | Anti-cd73 antibodies and methods of use thereof |
| CN110372800B (zh) * | 2019-08-27 | 2022-06-07 | 南京安吉生物科技有限公司 | 具有多功能活性的融合多肽及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6008011A (en) | 1991-10-31 | 1999-12-28 | Whitehead Institute For Biomedical Research | TGF-β type II receptor cDNAs |
| EP1149908A1 (en) | 1991-10-31 | 2001-10-31 | Whitehead Institute For Biomedical Research | TGF-beta type receptor cDNAs and uses thereof |
| US6395494B1 (en) | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
| ES2174868T3 (es) | 1992-10-29 | 2002-11-16 | Celtrix Pharma | Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico. |
| CN1257545A (zh) | 1997-04-18 | 2000-06-21 | 拜奥根有限公司 | Ⅱ型TGF－β受体/免疫球蛋白恒定区融合蛋白 |
| JP2001206899A (ja) * | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途 |
| US20030028905A1 (en) * | 2001-07-31 | 2003-02-06 | Petra Knaus | Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms |
| AU2002357362A1 (en) * | 2001-12-21 | 2003-07-30 | The Regents Of The University Of California | USE OF SOLUBLE TYPE II TGF-Beta RECEPTOR TO SUPPRESS PANCREATIC CANCER GROWTH AND METASTASIS |
| EP2171062A1 (en) | 2007-06-15 | 2010-04-07 | Genzyme Corporation | Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor |
| CN102850458B (zh) * | 2011-06-28 | 2014-10-01 | 华博生物医药技术（上海）有限公司 | 新型重组双功能融合蛋白及其制法和用途 |
-
2014
- 2014-12-18 AR ARP140104755A patent/AR098827A1/es unknown
- 2014-12-19 WO PCT/US2014/071338 patent/WO2015095628A1/en active Application Filing
- 2014-12-19 EP EP14872823.1A patent/EP3082846B1/en active Active
- 2014-12-19 US US15/105,162 patent/US10233227B2/en active Active
- 2014-12-19 ES ES14872823T patent/ES2749615T3/es active Active
-
2020
- 2020-05-29 AR ARP200101538A patent/AR119056A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR119056A2 (es) | 2021-11-17 |
| ES2749615T3 (es) | 2020-03-23 |
| WO2015095628A8 (en) | 2016-09-29 |
| US10233227B2 (en) | 2019-03-19 |
| US20160318989A1 (en) | 2016-11-03 |
| WO2015095628A1 (en) | 2015-06-25 |
| EP3082846A1 (en) | 2016-10-26 |
| EP3082846A4 (en) | 2017-09-20 |
| EP3082846B1 (en) | 2019-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2545895T3 (es) | Proteína de fusión anticancerígena | |
| AR119056A2 (es) | Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada | |
| AR094141A1 (es) | Composiciones y metodos para proteinas de accion prolongada | |
| CY1119916T1 (el) | Ανοσογονικη συνθεση | |
| CY1119149T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
| EA201491049A1 (ru) | Противораковый слитый белок | |
| EA201691111A1 (ru) | Химерные белки фактора viii и их применение | |
| EA201500802A1 (ru) | Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы | |
| PE20130041A1 (es) | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) | |
| EA201270517A1 (ru) | Микобактериальные вакцины | |
| EA201491277A1 (ru) | Противораковый слитый белок | |
| ES2531290T3 (es) | Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas | |
| GT201700224A (es) | Proteína de unión a rgma y su uso | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| AR093903A1 (es) | Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad | |
| AR102410A1 (es) | Polipéptidos que tienen actividad xilanasa con una tasa de conversión alta de polisacáridos que contienen xilosa | |
| CY1123997T1 (el) | Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου | |
| PE20170955A1 (es) | Nuevas proteinas inhibidoras de insectos | |
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
| NI201200085A (es) | Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina | |
| AR110093A1 (es) | D-psicosa 3-epimerasa y método para preparar d-psicosa utilizando la misma | |
| AR128395A2 (es) | Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9 | |
| EA201691011A1 (ru) | Последовательность модифицированного эндолизина el188 | |
| BR112017018703A2 (pt) | peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno | |
| EA201492068A1 (ru) | Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии |